IDV vehicle
75N91019D00022
PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMAKERS (POP: 01/25/2019 -01/24/2024
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NIH NCI |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | ORDER DEPENDENT (IDV ALLOWS PRICING ARRANGEMENT TO BE DETERMINED SEPARATELY FOR EACH ORDER) |
| Obligations | $0 |
| Current contract value | Not reported |
| Potential contract value / ceiling | $75.0M |
| Start date | Jan 25, 2019 |
| Current end date | Not available |
| Potential end date | Not available |
| Latest award activity | Jul 21, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 8 of 8 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Jul 21, 2026 | P00007 | $0 | EO 14398 PREVENT PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS |
| Jun 22, 2023 | P00006 | $0 | PREVENT PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS |
| Mar 28, 2023 | P00005 | $0 | PREVENT PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS |
| Nov 22, 2022 | P00004 | $0 | PREVENT PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS |
| Nov 16, 2021 | P00003 | $0 | EO14042 - PREVENT PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS |
| Aug 27, 2021 | P00002 | $0 | PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS |
| May 28, 2019 | P00001 | $0 | PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMAKERS (POP: 01/25/2019 -01/24/2024 |
| Jan 24, 2019 | 0 | $0 | PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMAKERS (POP: 01/25/2019 -01/24/2024 |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.